ONCOSTING LLC

Biotech · Private

Recombinant BCG vaccine engineered to overexpress STING agonist c-di-AMP for enhanced tuberculosis immunity

Claim this profile

Follows are private to you and power your alerts

Updated

Sector
Biotech
Total capital
$5.8M
Federal grants
$5.8M
7 awards · 2021–2025
Rank in peer group#123 of 514
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

20212022202320242025FEDERAL ↑EQUITY ↓Cumulative $5.8M$256K$907K$2M$1.1M$270K$991K
20212022202320242025FEDERAL ↑EQUITY ↓Cumulative $5.8M$907K$2M$1.1M$991K

Latest events

  • Federal grantHealth and Human S · Phase II · BCG overexpressing a small molecule STING agonist as a vaccine for TB$991K
  • Federal grantHealth and Human S · Phase II · BCG overexpressing a small molecule STING agonist as a vaccine for TB$270K
  • Federal grantHealth and Human S · Phase II · STING agonist-expressing BCG for bladder cancer$1.1M
  • Federal grantHealth and Human S · Phase II · STING agonist-expressing BCG for bladder cancer$2M
  • Federal grantHealth and Human S · Phase II · STING agonist-expressing BCG for bladder cancer$907K
  • Federal grantNSF · Phase I · STTR Phase I: Recombinant BCG as a novel immunoadjuvant for viral infections$256K
  • Federal grantHealth and Human S · Phase II · STING agonist-expressing BCG for bladder cancer$244K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

  • Federal grants#123 · top 24%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • Promentis PharmaceuticalsSimilar federal contract value in Biotech · null in contracts
  • SABER THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
  • BESSOR PHARMA, LLCSimilar federal contract value in Biotech · null in contracts
  • SPYRYX LLCSimilar federal contract value in Biotech · null in contracts
  • IONTX INC.Similar federal contract value in Biotech · null in contracts
  • MycoMedica Life Sciences, PBCSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .